iCAD’s Xoft Brain IORT Demonstrates Significant Improvement in Overall Survival in Recurrent Glioblastoma According to Comparative Study
In the IORT group, as of March 2021, both the overall survival (OS) and local progression free survival (locPFS) continued to be superior to those in the control group.
- In the IORT group, as of March 2021, both the overall survival (OS) and local progression free survival (locPFS) continued to be superior to those in the control group.
- One patient from the IORT group was still alive when this data was collected, whereas none of the patients in the control group survived.
- Additionally, a subgroup analysis of patients with post-operative contrast-enhancing volume (POCEV) of 2.5cm3 showed more favorable outcomes for patients in the IORT group.
- The median OS after re-resection for the IORT group was 21.25 months, versus 11.0 months for the control group.